Primary Care Research Unit, Department of General Practice, University of Melbourne, Carlton, Victoria, Australia.
Sex Transm Infect. 2010 Jun;86(3):181-6. doi: 10.1136/sti.2009.040188. Epub 2009 Dec 3.
To estimate for the first time the incidence and healthcare resource utilisation associated with genital warts (GW) in Australia prior to the human papillomavirus vaccination programme.
The authors analysed data from the nationally representative Bettering the Evaluation of Care and Health general practice cross-sectional programme and from the National Hospital Morbidity Database to estimate age-related incidence and community (non-hospital) and hospital-related costs (in 2009 Australian dollars) associated with medical treatment of GW.
The authors estimated an annual incidence of 2.19 cases of GW per 1000 Australians (95% CI 1.88 to 2.49), with peak incidence in women aged 20-24 years at 8.61 cases per 1000 and in men aged 25-29 years at 7.40 cases per 1000. The estimated number of consultations per GW case was 2.9 (95% CI 2.5 to 3.3) for women and 2.8 (95% CI 2.3 to 3.2) for men. Ablative treatments in general practice were more common in men (60% of consultations) than in women (37% of consultations). In contrast, more women (16% vs 8%) were referred to specialists, and 75% of ablative procedures requiring hospitalisation were performed in women. The annual cost of management of GW is over A$14 million, with an estimated cost per treated case of A$251 for men and A$386 for women.
GW impose a large health and cost burden on Australians. The national immunisation programme with the quadrivalent human papillomavirus vaccine has the potential to greatly reduce this burden, and future research measuring its impact is keenly anticipated.
首次估计澳大利亚人乳头瘤病毒疫苗接种计划前生殖器疣（GW）的发病率和医疗资源利用情况。
作者分析了全国代表性的改善保健和健康普通实践横断面计划以及国家医院发病率数据库的数据，以估计与 GW 医疗相关的年龄相关发病率以及社区（非医院）和医院相关成本（以 2009 年澳元计算）。
作者估计澳大利亚每年每 1000 人中有 2.19 例 GW 病例（95%CI 1.88 至 2.49），发病率峰值在 20-24 岁女性中为每 1000 人 8.61 例，在 25-29 岁男性中为每 1000 人 7.40 例。GW 每例病例的估计就诊次数为女性 2.9（95%CI 2.5 至 3.3）和男性 2.8（95%CI 2.3 至 3.2）。在普通实践中，消融治疗在男性中更为常见（60%的就诊）而不是女性（37%的就诊）。相比之下，更多的女性（16%比 8%）被转介给专家，需要住院的消融手术中有 75%是在女性中进行的。GW 的管理年度费用超过 1400 万澳元，估计每例治疗病例的费用为男性 251 澳元，女性 386 澳元。
GW 给澳大利亚人带来了巨大的健康和成本负担。四价人乳头瘤病毒疫苗的国家免疫计划有可能大大减轻这种负担，未来研究测量其影响备受期待。
